STOP PRESS: British Biotech press releases earn rebuke

Over optimistic press releases have earned pharmaceutical company British Biotech a rebuke from the US Securities and Exchange Commission. The UK company is the subject of a long-running SEC inquiry which is expected to be resolved shortly.

Over optimistic press releases have earned pharmaceutical company

British Biotech a rebuke from the US Securities and Exchange Commission.

The UK company is the subject of a long-running SEC inquiry which is

expected to be resolved shortly.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.